interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Copper

Generic competition · all medicines · read 12 November 2026

Is there a generic of Copper, and who makes it?

Copper appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Copper2 dosage-form groups in the Orange Book
0generic makers listed
  1. Copper appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Intrauterine Device, Intrauterine

Nothing listed as marketed

Every brand product here is listed as discontinued. No generic is listed as marketed.

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

System, Intrauterine

Brand listed, no generic listed as marketed

Brand listed as marketed: Miudella and Paragard T 380a. No generic is listed as marketed.

198019851990199520002005201020152020202520302035204001brand 1984data datePatent 9427351 listed to expire 14 August 2032Patent 11850181 listed to expire 14 August 2032Patent 10188546 listed to expire 14 August 2032Patent 10159596 listed to expire 14 August 2032Patent 9089418 listed to expire 9 April 2033Patent 12138199 listed to expire 18 October 2033Patent 10398588 listed to expire 24 February 2034Patent 9610191 listed to expire 24 February 2034Patent 10022264 listed to expire 22 March 2034Patent 9180040 listed to expire 22 March 2034Patent 9265652 listed to expire 28 April 2034Patent 10166141 listed to expire 13 June 2034Patent 11207209 listed to expire 16 August 2034Patent 10918516 listed to expire 23 January 2037Exclusivity D-193 to 28 June 2027Exclusivity NP to 24 February 2028
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 28 June 2027Exclusivity D-193 Paragard T 380a
  • 24 February 2028Exclusivity NP Miudella
  • 14 August 2032Patent 9427351 drug product
  • 14 August 2032Patent 11850181 drug product
  • 14 August 2032Patent 10188546 drug product
  • 14 August 2032Patent 10159596 drug product
  • 9 April 2033Patent 9089418 drug product
  • 18 October 2033Patent 12138199 drug product
  • 24 February 2034Patent 10398588 drug product
  • 24 February 2034Patent 9610191

6 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.